| Literature DB >> 33437790 |
Li-Yang Sun1, Hong Zhu2, Yong-Kang Diao1, Hao Xing3, Lei Liang1, Jie Li4, Ya-Hao Zhou5, Wei-Min Gu6, Ting-Hao Chen7, Yong-Yi Zeng8, Timothy M Pawlik9, Wan Yee Lau3,10, Chao Li3, Feng Shen3, Cheng-Wu Zhang1, Tian Yang1,3.
Abstract
EMAIL: zhangchengwuzr@hotmail.com; Prof. Tian Yang, MD. Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Navy Medical University, Shanghai 200438, China. Email: yangtiandfgd@hotmail.com.Entities:
Keywords: Albumin-bilirubin (ALBI); aspartate transaminase to platelet ratio index; aspartate transaminase-to-platelet ratio index (APRI); hepatocellular carcinoma (HCC); morbidity
Year: 2020 PMID: 33437790 PMCID: PMC7791207 DOI: 10.21037/atm-20-1421
Source DB: PubMed Journal: Ann Transl Med ISSN: 2305-5839
Figure 1Selection of the study population. HCC, hepatocellular carcinoma; ALBI, albumin-bilirubin; APRI, aspartate transaminase-to-platelet ratio index.
Comparisons of baseline characteristics, operative variables and postoperative outcomes
| Variables | Total (N=2,301) | ALBI | APRI | |||||
|---|---|---|---|---|---|---|---|---|
| The normal group (N=1,435) | The high group (N=866) | P value | The normal group (N=1,901) | The high group (N=400) | P value | |||
| Preoperative variables | ||||||||
| Age, years | 50.9±10.8 | 49.8±10.9 | 52.6±10.4 | <0.001 | 50.8±11.0 | 51.17±10.0 | 0.488 | |
| Sex, male/female | 2,038/263 (88.6/11.4) | 1,270/165 (88.5/11.5) | 768/98 (88.7/11.3) | 0.894 | 1,694/207 (89.1/10.9) | 344/56 (86.0/14.0) | 0.075 | |
| ASA score >2 | 290 (12.6) | 147 (10.2) | 143 (16.5) | <0.001 | 241 (12.7) | 49 (12.3) | 0.815 | |
| Diabetes mellitus | 131 (5.7) | 77 (5.4) | 54 (6.2) | 0.383 | 107 (5.6) | 24 (6.0) | 0.771 | |
| Obesity (BMI >30 m2/kg) | 80 (3.5) | 48 (3.3) | 32 (3.7) | 0.657 | 59 (3.1) | 21 (5.3) | 0.033 | |
| Anti-HCV (+) | 62 (2.7) | 27 (1.9) | 35 (4.0) | 0.002 | 48 (2.5) | 14 (3.5) | 0.274 | |
| HBsAg (+) | 2,079 (90.4) | 1,290 (89.9) | 789 (91.1) | 0.340 | 1,697 (89.3) | 382 (95.5) | <0.001 | |
| Cirrhosis | 1,715 (74.5) | 1,001 (69.8) | 714 (82.4) | <0.001 | 1,372 (72.2) | 343 (85.8) | <0.001 | |
| Portal hypertension | 509 (22.1) | 270 (18.8) | 239 (27.6) | <0.001 | 286 (15.0) | 223 (55.8) | <0.001 | |
| TB level (μmol/L) | 14.6±6.4 | 13.7±5.5 | 15.9±7.5 | <0.001 | 13.9±6.0 | 17.6±7.4 | <0.001 | |
| Albumin level (g/L) | 40.5±4.4 | 43.0±2.9 | 36.3±2.9 | <0.001 | 40.7±4.3 | 39.5±4.7 | <0.001 | |
| INR | 1.1±0.1 | 1.1±0.1 | 1.1±0.1 | <0.001 | 1.1±0.1 | 1.1±0.1 | <0.001 | |
| Platelets level (×109/L) | 144.9±69.9 | 149.4±65.6 | 137.5±75.9 | <0.001 | 157.82±66.9 | 83.7±47.7 | <0.001 | |
| ALT level, U/L | 36.0 (4.0–836.6) | 35.5 (4.0–467.2) | 37.8 (6.0–836.6) | 0.092 | 33.0 (4.0–413.0) | 62.5 (14.0–836.6) | <0.001 | |
| AST level, U/L | 35.0 (6.0–765.7) | 33.5 (6.0–335.1) | 38.0 (6.0–765.7) | <0.001 | 31.6 (6.0–159.4) | 69.4 (22.0–765.7) | <0.001 | |
| Child-Pugh score, A/B | 2,104/197 (91.4/8.6) | 1,415/20 (98.6/1.4) | 689/177 (79.6/20.4) | <0.001 | 1,785/116 (93.9/6.1) | 319/81 (79.8/20.3) | <0.001 | |
| MELD score | 4.4±2.9 | 4.0±2.8 | 4.9±2.9 | <0.001 | 4.1±2.8 | 5.4±2.9 | <0.001 | |
| Largest tumor size, cm | 6.2±4.0 | 5.8±3.7 | 6.7±4.4 | <0.001 | 6.1±4.0 | 6.3±4.5 | 0.456 | |
| Multiple tumors | 421 (18.3) | 263 (18.3) | 158 (18.2) | 0.960 | 345 (18.1) | 76 (19.0) | 0.689 | |
| Gross vascular invasion | 251 (10.9) | 139 (9.7) | 112 (12.9) | 0.016 | 191 (10.0) | 60 (15.0) | 0.004 | |
| Intraoperative variables | ||||||||
| Intraoperative blood loss | 300 (50–8,000) | 300 (50–5,000) | 350 (50–8,000) | <0.001 | 300 (50–8,000) | 450 (50–8,000) | <0.001 | |
| Intraoperative blood transfusion | 468 (20.3) | 225 (15.7) | 224 (25.9) | <0.001 | 320 (16.8) | 129 (32.3) | <0.001 | |
| Major hepatectomy | 532 (23.1) | 299 (20.8) | 176 (20.3) | 0.768 | 372 (19.6) | 103 (25.8) | 0.005 | |
| Non-anatomical hepatectomy | 1,701 (73.9) | 1,049 (73.1) | 652 (75.3) | 0.247 | 1,421 (73.8) | 300 (74.6) | 0.724 | |
| Postoperative outcomes | ||||||||
| Postoperative 30-day morbidity | 725 (31.5) | 383 (26.7) | 342 (39.5) | <0.001 | 556 (29.2) | 169 (42.3) | <0.001 | |
| Major morbidity | 260 (11.3) | 129 (9.0) | 131 (15.1) | <0.001 | 195 (10.2) | 65 (16.3) | 0.001 | |
| Minor morbidity | 465 (20.2) | 254 (17.7) | 211 (24.4) | <0.001 | 361 (19.0) | 104 (26.0) | <0.001 | |
| Perioperative 30-day mortality | 31 (1.3) | 8 (0.6) | 23 (2.6) | <0.001 | 15 (0.8) | 16 (4.0) | <0.001 | |
| Type of complications | ||||||||
| PHLF | 212 (9.2) | 111 (7.7) | 101 (11.7) | 0.002 | 158 (8.3) | 54 (13.5) | 0.001 | |
| Intra-abdominal hemorrhage | 22 (1.0) | 11 (0.8) | 11 (1.3) | 0.229 | 13 (0.7) | 9 (2.3) | 0.008 | |
| Bile leak | 25 (1.1) | 15 (1.0) | 10 (1.2) | 0.806 | 20 (1.1) | 5 (1.3) | 0.790 | |
| Pneumonia | 45 (2.0) | 18 (1.3) | 27 (3.1) | 0.002 | 34 (1.8) | 11 (2.8) | 0.207 | |
| Surgical site infection | 154 (6.7) | 74 (5.2) | 80 (9.2) | <0.001 | 120 (6.3) | 34 (8.5) | 0.112 | |
| Ascites | 132 (5.7) | 57 (4.0) | 75 (8.7) | <0.001 | 74 (3.9) | 58 (14.5) | <0.001 | |
| Pleural effusion | 462 (20.1) | 246 (17.1) | 216 (24.9) | <0.001 | 367 (19.3) | 95 (23.8) | 0.044 | |
| Others | 243 (10.6) | 133 (9.3) | 110 (12.7) | 0.009 | 188 (9.8) | 55 (1.8) | 0.022 | |
| Postoperative hospital stays, days | 12.8±6.6 | 13.6±6.4 | 12.3±6.9 | <0.001 | 12.6±6.6 | 14.0±6.7 | <0.001 | |
ALBI, albumin-bilirubin grade; ALT, alanine aminotransferase; APRI, aspartate transaminase to platelet ratio index; ASA, American Society of Anesthesiologists; AST, aspartate aminotransferase; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; INR, international normalized ratio; PHLF, post-hepatectomy liver failure; TB, total bilirubin.
Univariable and multivariable logistic regression analyses predicting overall morbidity in patients undergoing liver resection for hepatocellular carcinoma
| Variables | Univariate logistic regression | Multivariate logistic regression | ||||||
|---|---|---|---|---|---|---|---|---|
| Preoperative prediction model | Postoperative prediction model | |||||||
| Odds ratio (95% CI) | P value | Odds ratio (95% CI) | P value | Odds ratio (95% CI) | P value | |||
| Preoperative variables | ||||||||
| Age >60 years | 1.308 (1.057–1.619) | 0.013 | NS | 0.236 | NS | 0.156 | ||
| Male | 1.038 (0.786–1.371) | 0.792 | ||||||
| ASA score >2 | 1.561 (1.212–2.010) | 0.001 | 1.348 (1.032–1.760) | 0.028 | 1.319 (1.008–1.725) | 0.044 | ||
| Diabetes mellitus | 2.110 (1.480–3.009) | <0.001 | 2.053 (1.414–2.982) | <0.001 | 2.097 (1.440–3.055) | <0.001 | ||
| Obesity | 0.929 (0.571–1.512) | 0.768 | ||||||
| Anti-HCV (+) | 1.291 (0.765–2.178) | 0.338 | ||||||
| HBsAg (+) | 0.933 (0.694–1.252) | 0.643 | ||||||
| Cirrhosis | 1.960 (1.572–2.443) | <0.001 | 1.856 (1.478–2.331) | <0.001 | 1.874 (1.490–2.357) | <0.001 | ||
| Portal hypertension | 1.354 (1.101–1.664) | 0.004 | NS | 0.550 | NS | 0.933 | ||
| INR >1.17 | 1.286 (1.048–1.577) | 0.016 | NS | 0.874 | NS | 0.948 | ||
| ALT level >40 U/L | 0.930 (0.779–1.111) | 0.423 | ||||||
| High ALBI grade | 1.793 (1.498–2.145) | <0.001 | 1.518 (1.260–1.830) | <0.001 | 1.474 (1.221–1.780) | <0.001 | ||
| High APRI grade | 1.681 (1.346–2.100) | <0.001 | 1.538 (1.222–1.936) | <0.001 | 1.359 (1.074–1.720) | 0.011 | ||
| Largest tumor size >5 cm | 1.760 (1.470–2.106) | <0.001 | 1.802 (1.497–2.169) | <0.001 | NS | 0.432 | ||
| Multiple tumors | 1.018 (0.812–1.278) | 0.875 | ||||||
| Gross vascular invasion | 1.568 (1.198–2.052) | 0.001 | NS | 0.296 | NS | 0.708 | ||
| Intraoperative variables | ||||||||
| Intraoperative blood loss >400 mL | 1.983 (1.605–2.451) | <0.001 | NS | 0.497 | ||||
| Intraoperative blood transfusion | 2.112 (1.766–2.526) | <0.001 | 1.752 (1.445–2.125) | <0.001 | ||||
| Major hepatectomy | 1.262 (1.020–1.560) | 0.032 | 1.554 (1.282–1.885) | <0.001 | ||||
| Non-anatomical hepatectomy | 1.088 (0.889–1.332) | 0.411 | ||||||
ALBI, albumin-bilirubin grade; ALT, alanine aminotransferase; APRI, aspartate transaminase to platelet ratio index; ASA, American Society of Anesthesiologists; CI, confidence interval; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; INR, international normalized ratio; NS, no significance.
Univariable and multivariable logistic regression analyses predicting major morbidity in patients undergoing liver resection for hepatocellular carcinoma
| Variables | Univariate logistic regression | Multivariate logistic regression | ||||||
|---|---|---|---|---|---|---|---|---|
| Preoperative prediction model | Postoperative prediction model | |||||||
| Odds ratio (95% CI) | P value | Odds ratio (95% CI) | P value | Odds ratio (95% CI) | P value | |||
| Preoperative variables | ||||||||
| Age >60 years | 1.110 (0.812–1.518) | 0.513 | ||||||
| Male | 0.988 (0.660–1.480) | 0.953 | ||||||
| ASA score >2 | 1.486 (1.047–2.110) | 0.027 | NS | 0.154 | NS | 0.182 | ||
| Diabetes mellitus | 1.638 (1.016–2.641) | 0.043 | 1.664 (1.024–2.705) | 0.040 | 1.668 (1.025–2.717) | <0.001 | ||
| Obesity | 0.746 (0.340–1.638) | 0.465 | ||||||
| Anti-HCV (+) | 1.724 (0.887–3.351) | 0.108 | ||||||
| HBsAg (+) | 0.763 (0.509–1.142) | 0.188 | ||||||
| Cirrhosis | 1.775 (1.265–2.491) | 0.001 | 1.639 (1.160–2.317) | 0.005 | 1.647 (1.165–2.328) | 0.001 | ||
| Portal hypertension | 1.144 (0.845–1.548) | 0.384 | ||||||
| INR >1.17 | 1.309 (0.979–1.751) | 0.070 | NS | 0.457 | NS | 0.517 | ||
| ALT level >40 U/L | 1.104 (0.852–1.431) | 0.454 | ||||||
| High ALBI grade | 1.804 (1.392–2.339) | <0.001 | 1.565 (1.200–2.040) | 0.001 | 1.531 (1.173–1.999) | 0.002 | ||
| High APRI grade | 1.685 (1.244–2.284) | 0.001 | 1.524 (1.116–2.082) | 0.008 | 1.416 (1.030–1.946) | 0.008 | ||
| Largest tumor size >5 cm | 1.940 (1.477–2.547) | <0.001 | 1.890 (1.436–2.488) | <0.001 | NS | 0.477 | ||
| Multiple tumors | 1.102 (0.795–1.527) | 0.559 | ||||||
| Gross vascular invasion | 1.265 (0.859–1.862) | 0.235 | ||||||
| Intraoperative variables | ||||||||
| Intraoperative blood loss >400 mL | 1.616 (1.202–2.172) | 0.001 | NS | 0.681 | ||||
| Intraoperative blood transfusion | 1.766 (1.362–2.288) | <0.001 | 1.388 (1.052–1.832) | 0.021 | ||||
| Major hepatectomy | 1.522 (1.135–2.042) | 0.005 | 1.725 (1.296–2.295) | <0.001 | ||||
| Non-anatomical hepatectomy | 0.911 (0.682–1.217) | 0.529 | ||||||
ALBI, albumin-bilirubin grade; ALT, alanine aminotransferase; APRI, aspartate transaminase to platelet ratio index; ASA, American Society of Anesthesiologists; CI, confidence interval; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; INR, international normalized ratio; NS, no significance.
Figure 2The nomogram models for the prediction of overall morbidity [(A) preoperative and (B) postoperative] and major morbidity [(C) preoperative and (D) postoperative] for patients undergoing hepatectomy for hepatocellular carcinoma.
Figure 3Calibration curves of the nomograms comparing and actual and predicted probabilities of overall and major morbidity, including the predictive performance of preoperative (A) and the postoperative (B) nomograms for predicting overall morbidity, and preoperative (C) and the postoperative (D) nomograms for predicting major morbidity.
Figure 4Our Internet browser-based online calculators for the preoperative (A) and postoperative (B) prediction of overall and major morbidity for patients with hepatocellular carcinoma. (http://www.asapcalculate.top/Cal7_en.html). Probabilities of developing overall and major morbidity of a patient who underwent curative hepatectomy for HCC were calculated preoperatively (C) and postoperatively (D), respectively. HCC, hepatocellular carcinoma.
Figure 5Receiver operating characteristic curves of preoperative and postoperative prediction models, MELD, ALBI, and APRI scores, and Child-Pugh grade for predicting overall morbidity (A) and major morbidity (B). AUC, area under the receiver operating characteristic curve; CI, confidence interval; MELD, model for end-stage liver disease; ALBI, albumin-bilirubin; APRI, aspartate transaminase-to-platelet ratio index.